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Abstract: Secondary metabolites from marine organisms are a rich source of novel leads for drug
development. Among these natural products, polycyclic aromatic alkaloids of the pyridoacridine
type have attracted the highest attention as lead compounds for the development of novel anti-cancer
and anti-infective drugs. Numerous sophisticated total syntheses of pyridoacridine alkaloids have
been worked out, and many of them have also been extended to the synthesis of libraries of analogues
of the alkaloids. This review summarizes the progress in the chemistry of pyridoacridine alkaloids
that was made in the last one-and-a-half decades.
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1. Introduction
Pyridoacridine alkaloids are a fascinating and emerging class of polycylic alkaloids derived from
sessile marine invertebrates such as ascidians, sponges, mollusks, and sea anemones [1]. The era of this
alkaloid family started in 1983 with the isolation and identification of amphimedine (1) from a pacific
sponge (Amphimedon sp.) by Shoolery [2]. Since then, more than 100 of these polycyclic heteroaromatic
natural compounds have been isolated and, according to the biosynthetic considerations of Skyler and
Heathcock, a large number of “undiscovered“ alkaloids is assumed [3]. Pyridoacridines are highly
colored marine metabolites and are characterized by the 11H-pyrido[4,3,2-mn]acridine skeleton (2) [4]
(Figure 1). Besides a few hepta- and octacyclic members, tetra-, penta-, and hexacyclic compounds
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The  pyridoacridines  and  numerous  analogues  have  been  reported  to  possess  manifold 
biological  activities. The  outstanding  biological  effect  in  this  context  is  beyond doubt  their  high 
cytotoxicity. Various mechanisms of action have been described for these anticancer activities. The 
predominant effects are inhibition of topoisomerase II and the formation of reactive oxygen species 
(ROS).  Furthermore,  several  pyridoacridines  and  analogues  are  associated  with  antimicrobial, 
insecticidal and antiparasitic acitivities against Plasmodium, Leishmania, and Trypanosoma species  [1]. 
Figure 1. Structure of amphimedine (1) and the 11H-pyrido[4,3,2-mn]acridine scaffold (2).
The pyridoacridines and numerous analogues have been reported to possess manifold biological
activities. The outstanding biological effect in this context is beyond doubt their high cytotoxicity.
Various mechanisms of action have been described for these anticancer activities. The predominant
effects are inhibition of topoisomerase II and the formation of reactive oxygen species (ROS).
Furthermore, several pyridoacridines and analogues are associated with antimicrobial, insecticidal and
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antiparasitic acitivities against Plasmodium, Leishmania, and Trypanosoma species [1]. Consequently, this
alkaloid family is of great interest as a source of new lead structures in medicinal chemistry.
The pharmacology of pyridoacridine alkaloids has been reviewed comprehensively very
recently [5].
Since only minute amounts of these alkaloids can be obtained from natural sources, total synthesis
is an indispensable means for development of drugs from this chemotype. On the other hand, effective
strategies for the total syntheses of the alkaloids also open the opportunity for preparing synthetic
analogues of the natural products for getting deeper insight into structure-activity relationships and
improving pharmacokinetic and pharmacodynamic properties.
Several reviews on the chemistry of pyridoacridine alkaloids have been published over the
years [4], and the most recent one was authored by Delfourne in 2002 [6]. The present review represents
an update of Delfourne’s compilation, including some older work that is missing in [6].
2. Ascididemin-Type Pyridoacridines
Ascididemin (3) and closely related pyridoacridine alkaloids (bromoleptoclinidinone (4),
neocalliactine acetate (5), and 10-hydroxyascididemin (6)) share the same pentacyclic ring system, in
which a pyridine ring is annulated to ring A of the 11H-pyrido[4,3,2-mn]acridine scaffold (2) (Figure 2).
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regioselective  oxidative  amination  (51%  yield)  of  isoquinoline‐5,8‐dione  (10)  and 
2‐aminoacetophenone (7) as the key step (Scheme 2). 
Figure 2. Structures of the ascididemin-type pyridoacridine alkaloids: ascididemin (3),
bro oleptoclinidinone (4), neocalliactine acetate (5), 10-hydroxyascidide in (6).
The first and still-leading synthesis of the alkaloid acsididemin (3) was published by Bracher
in 1989 [7]. Albeit being presented in numerous reviews before, this synthesis is shown here once
again, since its crucial steps have found application in several of the more recent approaches to
diverse pyridoacridine alkaloids that will be presented below. The synthesis starts with an oxidative
amination of 2-aminoacetophenone (7) and quinoline-5,8-dione (8), followed by an acid-catalyzed
cyclization step to give tetracyclic quinone 9. The final annulation of ring E was performed in a
one-pot reaction by condensation of the acidic methyl group with N,N-dimethylformamide diethyl
acetal, followed by heating with ammonium chloride/glacial acetic acid to give 3 [7] (Scheme 1).
This high-yielding four-step approach (43% overall yield) has later been applied to the total synthesis
of many related pyridoacridines and analogues thereof by simply using pertinent ring-substituted
2-aminoacetophenones as starting materials [8–11].
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The isomer 11 of ascididemin, in which the nitrogen in ring A is shifted from position 13 to 11,
was prepared by the Delfourne group [12] in full analogy to Bracher’s method, with a surprisingly
Mar. Drugs 2016, 14, 26 3 of 24
regioselective oxidative amination (51% yield) of isoquinoline-5,8-dione (10) and 2-aminoacetophenone







Based  on  Bracher’s  synthetic  strategy  [7],  several  modified  approaches  towards 
ascididemin‐type  pyridoacridines  have  been  developed.  Most  of  these  syntheses  aim  at  the 
replacement of  the 2‐aminoacetophenone building block by more  complex 2‐substituted anilines, 
which bear a  residue  that  introduces not only C‐3 and C‐3a of  the  final pentacycle  (as  the acetyl 
residue does), but contain, in addition, equivalents of the later C‐2 an the ring nitrogen of ring E (for 
numbering  of  the  ring  system,  see  Scheme  1).  In  earlier  approaches, 
N‐trifluoroacetamidokynuramine  (bearing  a  protected  3‐aminopropanoyl  side‐chain)  [13]  and 
2‐aminocinnamaldehyde‐N,N‐dimethylhydrazone [14] were used for this purpose. 
In  a  very  recent  syntheses  of  various  ascididemin‐type  alkaloids,  consisting  of  the  natural 
products  ascididemin  (3),  bromoleptoclinidinone  (4),  neocalliactine  acetate  (5), 
10‐hydroxyascididemin  (6),  as well  as  two  synthetic  analogues  5‐methoxyascididemin  (17)  and 



















Scheme 2. Synthesis of ascididemin isomer 11. Reagents and conditions: (a) CeCl3¨ 7H2O, EtOH, air;
then conc. H2SO4/AcOH (27% over two steps); (b) N,N-dimethylformamide diethyl acetal, DMF; then
NH4Cl, AcOH (23% over two steps).
Based on Brach r’s synthetic strategy [7], several modified approaches towards ascididemin-type
pyridoacridines have been dev l ed. Most of these syntheses aim at the replacement of the
2-aminoacetophenone building block by more complex 2-substituted anilines, which bear a residue
that introduces not only C-3 and C-3a of the final pentacycle (as the acetyl residue does), but contain,
in addition, equivalents of the later C-2 an the ring nitrogen of ring E (for numbering of the ring
system, see Scheme 1). In earlier approaches, N-trifluoroacetamidokynuramine (bearing a protected
3-aminopropanoyl side-chain) [13] and 2-aminocinnamaldehyde-N,N-dimethylhydrazone [14] were
used for this purpose.
In a ve y recent syntheses of various ascididemin-type lkaloids, consisting of the natural products
ascididemin (3), bromoleptoclinidinone (4), neocalliactine ace a e (5), 10-hydroxyascididemin (6), as
well as two synthetic analogues 5-methoxyascididemin (17) and deazaascididemin (18), Yin et al.
introduced a novel C3N unit, the Boc-protected propargylamine group, for this purpose [15].
The required alkyne building blocks 12 were synthesized via Sonogashira reaction of the alkyne
N-Boc-propargylamine and a variety of 2-iodoanilines. In analogy to the original synthesis [7], this
approach started with an oxidative amination step of alkynylanilines 12 with quinones 13 and 14.
The so-obtained arylaminoquinones 15 and 16 were transferred to alkaloids 3–6, and analogues 17 and
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Scheme 3. ynthesis of pyridoacridine natural cts 3–6 and synthetic ascididemin analogues
5-methoxyascididemin (17) and deazaascidide in (18): (a) eCl3¨ 7H2O, MeOH, O2 (50 –80%);
(b) Fe2(SO4)3, conc. H2SO4/AcOH, O2 (44%–86%).
As a number of investigations on the biological activities of ascididemin-type pyridoacridines
indicated that cytotoxic activity and sele tivity ( .g., against human and prot z al cells) is strongly
dependent on the shape of ring A (especi lly the prese ce and position of heteroatoms in this
ring) [5,16–19], numer us investigations aim d at worki g out novel and flexibl appr aches to
ring A a alogu s of ascididemin (3) wer undertaken in the pas d cade.
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The approach described by Copp in 2010 [18] in general follows Bracher’s strategy [7], but the
authors utilized thiophene and furan quinones 19 and 20 instead of quinoline-5,8-dione (8) in order to
introduce heteroatom-containing five-membered ring A substitutes. The final annulation of ring E
(under concomitant rearomatization) was performed with paraformaldehyde and ammonium chloride
to give ascididemin-type pyridoacridines 21 and 22 (Scheme 4) [18].
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Scheme  5. Synthesis of ascididemin  (3)  through anionic  ring  closure:  (a) Malononitrile, NH4OAc, 
toluene/AcOH; (b) dimethylformamide dimethyl acetal, CH2Cl2; (c) HCl gas, AcOH (81% over three 
steps);  (d)  3‐methylpyridin‐2‐ylzinc bromide, PEPPSI‐iPr, THF  (80%);  (e) NaH, DMF;  (f) O2  (69% 





N,N’‐dimethylpropylene urea  (DMPU). However,  the yields of  the  final cyclization cascade were 
Scheme 4. Synthesis of ascididemin-type pyridoacridines 21 and 22 by Copp: (a) CeCl3¨ 7H2O, MeOH,
air (22%–92%); then conc. H2SO4/AcOH (81%–94%); (b) NH4Cl, (CH2O)n, AcOH (76%–83%).
A complet ly differ nt a proach towar s ascididemin (3) and its analogues using an anionic ring
closure as the key step was published by Kristensen in 2012 [20]. Synthesis of ascididemin (3) started
with a Knoevenagel condensation of 2’-fluoroacetophenone (23) and malononitrile. The CH-acidic
methyl group in the resulting product 24 was condensed with N,N-dimethylformamide dimethyl
acetal to give enamine 25. Upon exposure of 25 to HCl in glacial acetic acid cyclization to the
2-chloropyridine, 26 was accomplished. Negishi cross-coupling with 3-methylpyridin-2-yl zinc
bromide under PEPPSI-iPr catalysis gave the bipyridine 27, the central precursor for the anionic
cascade. Treating 27 with NaH in DMF under microwave irradiation furnished 9-deoxyascididemin
(28) vi an nionic ring closure c scade. As 28 proved to be very difficult to han le, the crude
intermediate was directly oxidize by bu bl g oxygen through the s lution. The desired alkaloid
3 was finally isolated in 45% overall yield (Scheme 5). An isomer of the alkaloid, prepared by using
4-methylpyridin-3-yl zinc bromide was obtained in the same manner in comparable overall yield.
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N,N’‐dimethylpropylene urea  (DMPU). However,  the yields of  the  final cyclization cascade were 
Scheme 5. Synthesis of a cididemin (3) through anionic ring closure: (a) Malononitrile, NH4OAc,
toluene/AcOH; (b) dimethylformamide dimethyl acetal, CH2Cl2; (c) HCl gas, AcOH (81% over three
steps); (d) 3-methylpyridin-2-ylzinc bromide, PEPPSI-iPr, THF (80%); (e) NaH, DMF; (f) O2 (69% over
two steps) [20]; Synthesis of the ring A analogues 18, 30–34; (g) Negishi or Suzuki cross-coupling
reactions (44%–88%); (h) NaH, DMPU (19%–29%).
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Based on this methodology, several ring A analogues of ascididemin 18, 30–34 were prepared
(Scheme 5) [21]. Different ring A equivalents were introduced via Neghishi or Suzuki cross-coupling
reactions to give biaryls 29. The following anionic ring closure was achieved here by using NaH in
N,N’-dimethylpropylene urea (DMPU). However, the yields of the final cyclization cascade were rather
low (12%–29%) here, and several target compounds bearing heteroarenes as ring E equivalents (among
them the annulated thiazole kuanoniamine A) could not be obtained at all.
In 2012, Raeder and Bracher published a new synthetic approach to the pyridoacridine ring system
involving two radical reactions as the key steps [22]. Readily available quinoline 35 was subjected
to Minisci benzoylation with a benzoyl radical generated from benzaldehyde to furnish ketone 36.
The initially low yield of this step was increased by replacing sulfuric acid by trifluoroacetic acid and by
adding additional amounts of radical starters (iron(II) sulfate, tert-butyl hydroperoxide) after intervals
of 45 min. The annulation of the bromopyridine ring, which later forms ring E of the target compound,
was accomplished in a two-step protocol. First, 36 was condensed with dimethylformamide diethyl
acetal, followed by heating with concentrated sulfuric acid/glacial acetic acid to give pyridone 37.
In the second step, 37 was converted to bromo compound 38 by heating with phosphoryl bromide.
The final intramolecular cyclization was performed through conversion of the bromopyridine moiety to
an aryl radical with tributyltin hydride and azobis(isobutyronitrile) (AIBN) to give deazaascididemin
(18) (Scheme 6). Unfortunately, this approach gives only a very low overall yield, and the scope of this
route has not been explored.
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In a related approach, Bracher [23] intended to utilize the Minisci reaction as a final cyclization
step for the synthesis of ascididemin (3). However, attempted acidic hydrolysis of dioxolane
39 (to give aldehyde 40 as an acyl radical precursor) resulted in unexpected cyclization to the
benzo[f ]pyrido[21,31:3,4]pyrrolo[2,1-a][2,7]naphthyridine 41 (Scheme 7).
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A different synthetic approach to ring A analogues of ascididemin from the Bracher group [24]
started with a high-yielding, regioselective Minsici-type homolytic methoxycarbonylati n at C-5
of readily available 4-brombenzo[c][2,7]naphthyrid ne (42), followed by n introduction of ring A
equivalents through Suzuki cross-coupling with appropriate (hetero)areneboronic acids. The final
intramolecular ring closure was achieved by tr ating the 4,5-disubstituted benzo[c][2,7]naphthyridines
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44 with trifluoromethanesulfonic acid under microwave irradiation. This final superacid-aided
Friedel-Crafts-type acylation step furnished pyridoacridines 18, 31, 45–48 in 63%–92% yields
(Scheme 8). Significantly lower yields were obtained with the corresponding ethyl esters.
However, these cyclization reactions were successful only with electron-rich aryl residues (phenyl,
naphthyl, thiophenes) in position 4. Electron-withdrawing substituents (acetyl, chloro, bromo) on a
benzene or thiophene ring led to the complete failure of this cyclization step [24].
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(C‐5) with Knochel’s TMPMgCl∙LiCl (2.2 equivalents), and intramolecular nucleophilic attack of the 
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KF,  THF  (73%–80%);  for  Negishi  cross‐coupling  reactions:  pyridylzinc  compounds,  Pd(dba)2,   
P(2‐furyl)3, THF (71%–76%); (b) TMPMgCl∙LiCl, THF (27%–39%). 
Scheme 8. Synthesis of ring A analogues of ascididemin 18, 31, 45–48 through an intramolecular
trifluoromethanesulfonic acid-aided Friedel-Crafts-type cyclization step: (a) Methyl pyruvate, H2O2,
FeSO4, H2SO4, AcOH; then MnO2, CH2Cl2 (93% over two steps); (b) (hetero)areneboronic acid,
Pd(Ph3P)4 (cat.), K2CO3, THF, H2O (41%–75%); (c) CF3-SO3H, microwave irradiation (63%–92%).
Due to the fact that the above-mentioned protocol [24] only allows for the introduction of
electron-rich carbocyclic and heterocyclic ring A substitutes, Plodek et al. developed a new approach
to the pyridoacridine ring system in which electron-deficient (hetero)arenes also serve as sources for
ring A [25]. T e introduction of the ring A scaffolds was achieved through Suzuki cross-coupling
of 4-brombe zo[c][2,7]naphthy idine (42) with ( etero)aren boronic acids bearing an ester moiety
in the ortho position or through Negishi cross-coupling with pyridylzinc compounds which were
obtained by regioselective ring metalation of ethyl nicotinate or ethyl isonicotinate. The resulting
5-substituted benzo[c][2,7]naphthyridines 49 were metalated regioselectively at the peri position (C-5)
with Knochel’s TMPMgCl¨ LiCl (2.2 equivalents), and intramolecular nucleophilic attack of the resulting
arylmagnesium species 50 at the ester group furnished ring A analogues 18, 31, 45–48 and isomers
11 and 30 of ascididemin in poor-to-modest yields (Scheme 9) [25]. This key step was inspired by the
synthesis of demethyldeoxyamphimedine published by the Bracher group in 2014 [26] (see below).
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Scheme 9. TMPMgCl¨ LiCl-mediated synthesis of ring A analogues 18, 31, 45–48 and isomers 11 and 30
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The protocol shown in Scheme 9 is the most flexible one for the preparation of ring A analogues
of ascididemin (3), which are of special interest for the development of anticancer compounds.
3. Amphimedine-Type Pyridoacridines
Amphimedine-type pyridoacridines consist of the pentacyclic alkaloids amphimedine (1),
neoamphimedine (54), deoxyamphimedine (55), and demethyldeoxyamphimedine (56) (Figure 3) [26].
Compared to the ascididemin subclass, rings A and B are connected in a different manner here.
While most of the published syntheses of ascididemin-type pyridoacridines are more or less based on
Bracher’s synthetic methodology [7], many different and versatile strategies towards the amphimedine
scaffold have been developed [6]. During the last 15 years, three approaches towards neoamphimedine
(54) and two syntheses of demethyldeoxyamphimedine (56) have been reported.
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c e e 10. Synthesis of demethyldeoxyamphimedine (56): (a) Toluene, N2 atmosphere (0.8%);
(b) NaOH, HCl3 (96%).
highly effective total synthesis of demethyldeoxyamphimedine (56) was reported by Melzer et al.
in 2014 [26]. Regioselective direct metalation of ethyl nicotinate (61) at C-4 using TMPMgCl¨ BF3¨ LiCl
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and subsequent transmetalation with ZnCl2 gave pyridylzinc compound 62, which was directly
subjected to a Negishi cross-coupling reaction with 2-iodoaniline. The resulting biaryl (not shown
in Scheme 11) underwent spontaneous lactamization to give benzo[c][2,7]naphthyridin-5(6H)-one
(63). This lactam was converted to 5-bromobenzo[c][2,7]naphthyridine (64) with phosphoryl bromide.
In another Negishi cross-coupling reaction, tricyclus 64 was coupled with organozinc intermediate 62 to
give biaryl 65. The final ring closure step was achieved via direct regioselective metalation at C-4 of 65
utilizing 2.2 equivalents of Knochel’s TMPMgCl¨ LiCl, followed by intramolecular trapping of the ester
group to give alkaloid 56 in 6.4% total yield. Thus, the authors prepared demethyldeoxyamphimedine
(56) by using only two commercial building blocks, ethyl nicotinate and 2-iodoaniline (Scheme 11) [26].
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Catalytic  reduction and  following  conversion with  ethyl  (2‐nitrobenzoyl)acetate  furnished  β‐keto 
amide 68  in very good yields. Treatment of 68 with polyphosphoric acid gave quinolone 69  in a 
Knorr cyclization  reaction. Quinoline 70 was obtained  in a  two‐step protocol  through  treating 69 
with  trifluoromethanesulfonic  anhydride  and  subsequent  hydrogenolysis  of  the  resulting  triflate 
ester. The following transformation of the 7‐acetylamino group of 70 into a nitrile was accomplished 
under  Sandmeyer  conditions  after  acidic  hydrolysis. Next,  the  nitrile  of  71 was  hydrolyzed  by 
heating with concentrated sulfuric acid  to give  the carboxylic acid 72, and  further amidated with 
N‐methylamino  acetaldehyde  dimethylacetal  to  give  carboxamide  73.  Pomeranz‐Fritsch–type 
cyclization with sulfuric acid gave oxo‐diazaanthracene 74. The desired alkaloid 54 was obtained by 
catalytic  reduction  of  the  nitro  group  of  74,  subsequent  CAN  oxidation  to  a  tricyclic  quinone, 
followed by intramolecular condensation with the amino group in a total yield of 2% over 12 steps 
(Scheme 12) [28]. 
Based  on  this  methodology,  LaBarbera  published  an  improved  total  synthesis  of 
neoamphimedine  (54)  [29]. The central quinolone  intermediate 77 was synthesized  in  three steps, 
starting  from  nitrobenzoate  75.  Catalytic  hydrogenation  of  75  gave  the  aniline  76,  which  was 
converted  to  77  by  treatment with Meldrum’s  acid  and  trimethyl  orthoformate.  The  following 
thermal  ring  closure  gave  4‐quinolone  78 with  an  overall  yield  of  78%.  Treatment  of  78 with 
trifluoromethanesulfonic anhydride furnished triflate ester 79, which was smoothly converted to the 
biaryl 81 in a Stille cross‐coupling reaction with readily available trimethyl‐(2‐nitrophenyl)stannane 
(80). Next, alkaline hydrolysis of  the methyl ester group gave  carboxyclic acid 72. The  following 
steps were performed as described above  [28] and afforded neoamphimedine  (54)  in 25% overall 
yield (Scheme 13) [29]. 
Scheme 11. Synthesis of demethyldeoxyamphimedine (56) by Melzer et al: (a) TMPMgCl¨ BF3¨ LiCl,
THF; then ZnCl2; (b) 2-iodoaniline, Pd(dba)2, P(2-furyl)3, THF (50% over two steps); (c) POBr3 (59%);
(d) pyridylzinc compound 62, Pd(dba)2, P(2-furyl)3, THF (78%); (e) TMPMgCl¨ LiCl, THF (28%).
The first total synthesis of neoamphimedine (54) was reported by Ireland in 2007 [28].
This approach started with O-methylation of dinitrophenol 66 with diazomethane, followed by
selective reduction of one of the two nitro groups with 10% palladium on carbon and subsequent
acetylation of the so-obtained amine (not shown in Scheme 12) with acetic anhydride to afford
acetanilide 67. Catalytic reduction and following conversion with ethyl (2-nitrobenzoyl)acetate
furnished β-keto amide 68 in very good yields. Treatment of 68 with polyphosphoric acid gave
quinolone 69 in a Knorr cyclization reaction. Quinoline 70 was obtained in a two-step protocol
through treating 69 with trifluoromethanesulfonic anhydride and subsequent hydrogenolysis of
the resulting triflate ester. The following transformation of the 7-acetylamino group of 70 into a
nitrile was accomplished under Sandmeyer conditions after acidic hydrolysis. Next, the nitrile
of 71 was hydrolyzed by heating with concentrated sulfuric acid to give the carboxylic acid 72,
and further amidated with N-methylamino acetaldehyde dimethylacetal to give carboxamide 73.
Pomeranz-Fritsch–type cyclization with sulfuric acid gave oxo-diazaanthracene 74. The desired
alkaloid 54 was obtained by catalytic reduction of the nitro group of 74, subsequent CAN oxidation to
a tricyclic quinone, followed by intramolecular condensation with the amino group in a total yield of
2% over 12 steps (Scheme 12) [28].
Based on this methodology, LaBarbera published an improved total synthesis of neoamphimedine
(54) [29]. The central quinolone intermediate 77 was synthesized in three steps, starting from
nitrobenzoate 75. Catalytic hydrogenation of 75 gave the aniline 76, which was converted to 77 by
treatment with Meldrum’s acid and trimethyl orthoformate. The following thermal ring closure gave
4-quinolone 78 with an overall yield of 78%. Treatment of 78 with trifluoromethanesulfonic anhydride
furnished triflate ester 79, which was smoothly converted to the biaryl 81 in a Stille cross-coupling
reaction with readily available trimethyl-(2-nitrophenyl)stannane (80). Next, alkaline hydrolysis of
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the methyl ester group gave carboxyclic acid 72. The following steps were performed as described
above [28] and afforded neoamphimedine (54) in 25% overall yield (Scheme 13) [29].Mar. Drugs 2016, 14, x  9 of 24 
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Scheme 13. Improved synthesis of neoamphimedine (54): (a) Pd/C, H2, MeOH; (b) Meldrum’s acid,
trimethyl orthoformate (90% over two steps); (c) Ph2O, reflux (87%); (d) Tf2O, DMAP, 2,6-lutidine,
CH2Cl2 (92%); (e) trimethyl-(2-nitrophenyl)stannane (80), CuI, Pd(OAc)2, dppe, DMF (83%); (f) LiOH;
following steps, see Scheme 12.
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Another synthetic approach to neoamphimedine (54) was reported by Nakahara et al. in 2012 [30].
Commercially available 2,5-dimethoxyphenethylamine (82) was N-acylated with ethyl chloroformate
and triethylamine. N-Methylation of the so-obtained N-carbethoxy derivative (not shown in Scheme 14)
was performed with methyl iodide and sodium hydride. Subsequent Bischler-Napieralski–type
cyclization with triflic anhydride and N,N-dimethylaminopyridine (DMAP) furnished quinolone
83 in 74% overall yield. Following regioselective nitration of 83 with cupric nitrate trihydrate
in acetic anhydride afforded 84 in excellent yield. Catalytic hydrogenation of the nitro group
utilizing 10% palladium on carbon and subsequent reaction with Meldrum’s acid and trimethyl
orthoformate yielded enamine 85, which was cyclized to acridinedione 86 by heating in diphenyl
ether. Subsequent bromination with phosphoryl bromide afforded 87, and Suzuki cross-coupling with
2-(pivaloylamino)phenylboronic acid gave intermediate 88 in high yield. Acid-mediated removal of
the pivaloyl protective group gave amine 89. Conversion to the alkaloid 54 was performed in two
steps: O-demethylation with BBr3 gave a hydroquinone intermediate which underwent cyclization
and dehydrogenation in the dihydropyridone ring upon oxidation with CAN (31% yield over both
steps). Using nitric acid as the oxidant led to a significant loss in yield (6%). The total yield of
neoamphimedine (54) over 12 steps was 6% (Scheme 14) [30].
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toluene (90%); (g) H2SO4/H2O (64%); (h) BBr3, CH2Cl2; then CAN/H2O, MeCN (31%).
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The symmetrical alkaloid eilatin (90, Figure 4) is the only known heptacyclic member of the
pyridoacridine alkaloid class and was isolated in 1988 by Rudi et al. from the tunicate Eudistoma
sp. [31]. Since synthetic approaches towards eilatin (90) have not been reviewed before, this chapter
will close this gap and gives a short overview on all published syntheses since its isolation.
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AcOH (75% over two steps); (g) 10% Pd/C, EtOH (85%). 
In  a  closely  related  approach,  the  same  authors  synthesized  eilatin  (90)  starting  from   
quinolone‐5,8‐dione  98  bearing  a  trifluoroacetyl‐protected  amino  group  at  the  phenyl  ring. 
Regioselective  CeCl3‐catalyzed  oxidative  amination  of  98  and  2‐aminoacetophenone  furnished, 
obviously under spontaneous N‐deprotection/cyclocondensation, the  tetracyclic aminoquinone 99. 
After an acid‐catalyzed cyclization step, which afforded hexacyclus 100, eilatin (90) was obtained in 
Figure 4. Structure of eilatin (90).
The first total synthesis of eilatin (90), which is illustrated in Scheme 15, was reported by the Kubo
group in 1993 [32]. The alkaloid was obtained in seven steps (overall yield 13%) from intermediate
91, which had been developed before as intermediate for a tot synthesis of a phimedine (1) [33].
Arylquinolone 91 was converted to the aryl triflate 92 with trifluoromethanesulfonic anhydride, and
subsequent palladium-catalyzed reductive removal of the sulfonyloxy group with triethylammonium
formate furnished 4-arylquinoline 93. Following oxidative demethylation of 93 using CAN gave
p-quinone 94. The next three steps follow Bracher’s asci idemine synthesis (see Scheme 1), thus
arylaminoqui oline-5,8-dione 95 was prepared by regioselective oxidative a ination of p-quinone
94 with 2-aminoacetophenone in the presence of CeCl3. Next, an acid-catalyzed cyclization step
was performed furnishing tetracyclic quinone 96, and the annulation of ring G was achieved using
condensation with N,N-dimethylformamide diethyl acetal followed by ammonium chloride treatment
to afford pentacyclus 97. The final ring closure step was accomplished through catalytic hydrogenation
of the nitro compound 97 with 10% palladium on carbon and spontaneous cyclocondensation to give
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Scheme 15. Synthesis of eilatin (90): (a) Tf2O, CH2Cl2, Et3N (93%); (b) formic acid, Et3N, Pd(OAc)2,
dppf, DMF (87%); (c) CAN, acetonitrile/H2O (60%); (d) CeCl3¨ 7H2O, 2-aminoacetophenone, EtOH
(54%); (e) conc. H2SO4/AcOH (83%); (f) N,N-dimethylformamide diethyl acetal, DMF; then NH4Cl,
AcOH (75% over two steps); (g) 10% Pd/C, EtOH (85%).
In a closely related approach, the same authors synthesized eilatin (90) starting from
quinolone-5,8-dione 98 bearing a trifluoroacetyl-protected amino group at the phenyl ring.
Regioselective CeCl3-catalyzed oxidative amination of 98 and 2-aminoacetophenone furnished,
obviously under spontaneous N-deprotection/cyclocondensation, the tetracyclic aminoquinone 99.
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After an acid-catalyzed cyclization step, which afforded hexacyclus 100, eilatin (90) was obtained in a




a  one‐pot  annulation  of  ring  G  using  N,N‐dimethylformamide  diethyl  acetal  and  ammonium 
chloride (Scheme 16) [32]. 
 
Scheme 16. Synthesis of eilatin  (90):  (a) CeCl3∙7H2O, 2‐aminoacetophenone, EtOH  (52%);  (b) conc. 
H2SO4/AcOH (75%); (c) N,N‐dimethylformamide diethyl acetal, DMF; then NH4Cl, AcOH (41% over 
two steps). 




in  very  low  yield.  Treatment  of  103 with  ammonia  in methanol  and DMAP  directly  furnished 
alkaloid 90. An alternative route towards eilatin (90) was accomplished by the treatment of 103 first 
with  BF3  etherate.  The  so‐obtained  pentacyclus  104 was  converted  to  eilatin  (90)  under  alkaline 
conditions  (NH3‐MeOH)  (Scheme  17)  [34].  No  yields  were  given  for  the  final  steps  in  both 
approaches. 
 
Scheme  17. Biomimetic  synthesis of  eilatin  (90):  (a) NaIO3, EtOH  (15%);  (b) BF3∙OEt2, CH2Cl2  (no 
yield given); (c) NH3, MeOH (no yield given) [34]. 








Scheme 16. Synthesis of eilatin (90): (a) CeCl3¨ 7H2O, 2-aminoacetophenone, EtOH (52%); (b) conc.
H2SO4/AcOH (75%); (c) N,N-dimethylformamide diethyl acetal, DMF; then NH4Cl, AcOH (41% over
two steps).
Kashman’s biomimetic approach towards eilatin (90) suggests that kynuramine and
o-benzoquinone (or the corresponding catechol, 102), both natural products, can be considered as
potential biosynthetic precursors of this alkaloid. In the first step, the monoprotected trifluoroacetyl
kynuramine 101 was reacted with catechol (102) under oxidative conditions to give compound 103 in
very low yield. Treatment of 103 with ammonia in methanol and DMAP directly furnished alkaloid
90. An alternative route towards eilatin (90) was accomplished by the treatment of 103 first with BF3
etherate. The so-obtained pentacyclus 104 was converted to eilatin (90) under alkaline conditions
(NH3-MeOH) (Scheme 17) [34]. No yields were given for the final steps in both approaches.
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c e e 17. Bio i etic synthesis of eilatin (90): (a) NaIO3, EtOH (15%); (b) BF3¨ OEt2, CH2Cl2 (no yield
given); (c) NH3, MeOH (no yield given) [34].
In this and an acco panying paper [35] the ash an group described several unsuccessful
approaches to eilatin (90). ne of these atte pts is illustrated in Sche e 18. In a conversion closely
related to the one described in Scheme 17, compound 105 was prepared from 2-aminoacteophenone (7)
and catechol (102) under oxidative conditions. Ring closure was accomplished by treating 105 with
BF3-etherate and this furnished the symmetrical pentacyclic dibenzo-1,10-phenanthroline-5,6-dione
106 in high yield. A completion of this synthesis (annulation of rings F and G of eilatin) has not yet
been published.
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Scheme 18. Synthesis of postulated eilatin precursor 106: (a) NaIO3, EtOH (60%); (b) BF3¨ OEt2,
CH2Cl2 (70%).
The synthetic strategy employed by Glazer and Tor [36] for the preparation of a RuII-eilatin
complex started with “pre-eilatin” (107), a formal seco analogue of the alkaloid, which was obtained in
54% yield by Pd-catalyzed homo-coupling of 4-bromobenzo[c][2,7]naphthyridine (42). Treatment of
“pre-eilatin” (107) with Ru(bpy)2Cl2¨ 5H2O in ethylene glycol and water gave the dark-red RuII complex
108 ([Ru(bpy)2(pre-eilatin)]2+), which was converted into the deep-green [Ru(bpy)2(eilatin)]2+ complex
109 by exposure to palladium on carbon in ethylene glycol and acetone at elevated temperatures in
almost quantitative yield. Separation of free eilatin from the complex 109 is not mentioned in the
publication. It is noteworthy that treatment of the free “pre-eilatin” (107) ligand with Pd/C did not
yield eilatin (90) (Scheme 19). This approach is quite short, but affords stoichiometric amounts of the
expensive Ru complex for the key step.
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A divergent synthesis leading to both eilatin (90) and its isomer isoeilatin (119) was published 
by  Plodek  and  Bracher  in  2015  [37].  This  approach  started  with  a  Friedländer  reaction  of   
2‐aminoacetophenone (7) and 1,3‐cyclohexanedione (110) to afford acridone 111. Following one‐pot 
annulation of a pyridine‐N‐oxide ring was accomplished by condensation of the acidic methyl group 
of  111  with  N,N‐dimethylformamide  diethyl  acetal  under  controlled  conditions  (55  °C)  and 
subsequent ring closure with hydroxylamine hydrochloride to give N‐oxide 112. In a Boekelheide 
rearrangement,  this N‐oxide was  converted  to  the acetoxy  compound 113 by heating with  acetic 
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Scheme 19. Synthesis of RuII-eilatin complex 109: (a) Pd(OAc)2, Bu4NBr, K2CO3, iPrOH, DMF (b)
Ru(bpy)2Cl2¨ 5H2O, ethylene glycol, water (62%); (c) Pd/C, ethylene glycol-acetone (97%).
A divergent synthesis leading to both eilatin (90) and its isomer isoeilatin (119) was published
by Plodek and Bracher in 2015 [37]. This approach started with a Friedländer reaction of
2-aminoacetophenone (7) and 1,3-cyclohexanedione (110) to afford acridone 111. Following one-pot
annulation of a pyridine-N-oxide ring was accomplished by condensation of the acidic methyl
group of 111 with N,N-dimethylformamide diethyl acetal under controlled conditions (55 ˝C) and
subsequent ring closure with hydroxylamine hydrochloride to give N-oxide 112. In a Boekelheide
rearrangement, this N-oxide was converted to the acetoxy compound 113 by heating with acetic
anhydride. Alkaline ester hydrolysis of 113 afforded alcohol 114 in 84% yield. Subsequent oxidation of
this alcohol under mild conditions with MnO2 under concomitant ring dehydrogenation furnished
pyridoacridone 115 in 66% yield. Further conversion to eilatin (90) was performed in analogy to
Bracher’s total synthesis of ascididemin (3) [7]. Thus, regioselective oxidative amination of 115 with
2-aminoacetophenone under CeCl3 catalysis gave arylamino derivative 99. Next, acid-catalyzed
cyclization furnished hexacyclic compound 100 in almost quantitative yield. The final annulation
of ring G was performed in a one-pot reaction by condensation of the acidic methyl group with
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N,N-dimethylformamide diethyl acetal, followed by heating with ammonium chloride/glacial acetic
acid to give 90. Hence, alkaloid 90 was synthesized in seven steps with an overall yield of 6.9% from
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Scheme  21.  Synthesis  of  isoeilatin  (119):  (a) mCPBA, CH2Cl2  (88%);  (b) N,N‐dimethylformamide 
diethyl acetal, DMF; then NH4Cl (38% over two steps); (c) acetic anhydride (80%); then 10% NaOH in 




in  1994.  Reaction  of  monoprotected  trifluoroacetyl  kynuramine  101  and 
2,5‐dihydroxy‐1,4‐cyclohexanedione (120) under acidic conditions (AcOH/Et3N) furnished isoeilatin 
Scheme 20. Synthesis of eilatin (90): (a) Reflux (54%); (b) N,N-dimethylformamide diethyl acetal, DMF;
then NH2OH¨ HCl (41% over two steps); (c) acetic anhydride (66%); (d) 10% NaOH in H2O/MeOH
(84%); (e) MnO2 (66%); (f) 2-aminoacetophenone, CeCl3¨ 7H2O (74%); (g) 10% H2SO4 in AcOH (96%);
(h) N,N-dimethylformamide diethyl acetal, DMF; then NH4Cl (65% over two steps).
Isoeilatin (119), a synthetic isomer of 90, was prepared from the same building blocks
by using different reaction conditions. In this synthesis, acridone 111 was first treated with
meta-chloroperoxybenzoic acid (mCPBA) to furnish N-oxide 116. An annulation of a pyridine ring
through condensation with N,N-dimethylformamide diethyl acetal and subsequent ring closure with
ammonium chloride gave tetracyclic compound 117, an isomer of the N-oxide 112 utilized in the
synthesis f eilatin (90), in 38% yield. In an logy to the above-mentioned prot col, N-oxide 117
was subjected to Boekelheide rearrangement, ester hydrolysis and oxidati with MnO2 to furnish
pyridoacridone 118. The following steps (oxidative amination, acid-catalyzed cyclization, annulation
of the seventh ring using N,N-dimethylformamide diethyl acetal and ammonium chloride) were
performed in full analogy to the above-mentioned total synthesis of eilatin (90) [37]. Isoeilatin (119)
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Scheme  21.  Synthesis  of  isoeilatin  (119):  (a) mCPBA, CH2Cl2  (88%);  (b) N,N‐dimethylformamide
diethyl acetal, DMF; then NH4Cl (38% over two steps); (c) acetic anhydride (80%); then 10% NaOH in 




in  1994.  Reaction  of  monoprotected  trifluoroacetyl  kynuramine  101  and 
2,5‐dihydroxy‐1,4‐cyclohexanedione (120) under acidic conditions (AcOH/Et3N) furnished isoeilatin 
Scheme 21. Synthesis of isoeilatin (119): (a) mCPBA, CH2Cl2 (88%); (b) N,N-dimethylformamide
diethyl acetal, DMF; then NH4Cl (38% over two steps); (c) acetic anhydride (80%); then 10% NaOH
in H2O/MeOH; then MnO2, toluene (50% over two steps); (d) 2-aminoacetophenone, CeCl3¨ 7H2O;
then 10% H2SO4 in AcOH; then N,N-dimethylformamide diethyl acetal, DMF; then NH4Cl (38% over
four steps).
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Another approach towards isoeilatin (119) was reported by Kashman [38] in a paper
published in 1994. Reaction of monoprotected trifluoroacetyl kynuramine 101 and 2,5-dihydroxy-
1,4-cyclohexanedione (120) under acidic conditions (AcOH/Et3N) furnished isoeilatin precursor 121
in 7% yield. Following treatment of with ammonia in methanol provided isoeilatin (119) (Scheme 22).
The authors also described the synthesis of a dibenzo analogue of eilatin (125) in this
publication [38]. For this purpose, 2,21-diaminobenzophenone (122) was reacted with o-benzoquinone
(123) in the presence of CeCl3 to give compound 124. Subsequent treatment with acid
(AcOH/H2SO4/Et3N) of 124 afforded the highly symmetrical “dibenzoeilatin” (125) (Scheme 22) [38].
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analogues  of  styelsamine  and  cystodytin  alkaloids  in  2013  [45]. The  key  step  of  this  biomimetic 
strategy is a CeCl3‐catalyzed oxidative coupling of kynuramine (141) and functionalized dopamine 
analogues 142–147  in  the presence of  silver oxide. While kynuramine  (141) was prepared  from a   
N‐protected tryptamine via oxidative cleavage of the pyrrole ring, the dopamine analogues 142–147 
Scheme 22. Synthesis of isoeilatin (119): (a) AcOH/Et3N (7%); (b) NH3 in methanol (43%). Synthesis of
dibenzoeilatin (125); (c) CeCl3¨ 7H2O, EtOH (36%); (d) AcOH/H2SO4/Et3N (no yield given).
5. Styelsamine- and Cystodytin-Type Pyridoacridines
Styelsamine- and cystodytin-type pyridoacridines are teracyclic alkaloids bearing a functionalized
side-chain at C-6. In contrast to cystodytin-type alkaloids, which possess the pyrido[4,3,2-mn]
acridin-4-one skeleton, styelsamine alkaloids are characterized by the hydroxylated pyrido[4,3,2-mn]
acridine core. Until today, four stylesamine-type (stylesamines A–D; 126–129) [39] and 11 cystodytin-
type alkaloids (cystodytin A–K; 130–140) [40–43] have been isolated and characterized (Figure 5).
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Based on Skyler and Heathcock’s biomimetic approach [44] to stylesamine B (127) and cystodytin
J (139), Fong and Copp reported the synthesis of a series of side-chain substituted analogues of
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styelsamine and cystodytin alkaloids in 2013 [45]. The key step of this biomimetic strategy is a
CeCl3-catalyzed oxidative coupling of kynuramine (141) and functionalized dopamine analogues
142–147 in the presence of silver oxide. While kynuramine (141) was prepared from a N-protected
tryptamine via oxidative cleavage of the pyrrole ring, the dopamine analogues 142–147 were
synthesized from 3,4-dimethoxyphenethylamine by N-acylation and subsequent O-demethylation
(both syntheses are not shown in Scheme 23). In situ oxidation of the catechol moiety of the
dopamines with silver oxide gives ortho-quinones, which undergo CeCl3-mediated nucleophilic
addition of the aromatic amino group of kynuramine (141) (the more basic aliphatic side-chain
amino group is prevented from this reaction by protonation) and re-oxidation to an aminoquinone.
Subsequent treatment with 6 M hydrochloric acid resulted in cyclization to the acridines and, finally,
closure of the fourth ring in an imine formation/tautomerization sequence related to a protocol that is
known from Kashman’s biomimetic ascididemin synthesis [13]. The stylesamine-type pyridoacridines
127, 148–152 were isolated in yields of 6% to 20%. Subsequent oxidation of 127, 148–152 with one
equivalent of silver oxide in bicarbonate-buffered methanol furnished cystodytin-type pyridoacridines
139, 153–157 in 13%–79% yields (Scheme 23) [45].
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different  conditions,  N,N‐dimethylformamide  dimethyl  acetal  at  145  °C,  but  the  same  yield) 
furnished  enamine  169  in  91%  yield.  Subsequent  oxidative  cleavage with NaIO4  in  THF/water 
afforded aldehyde 170  in 90% yield. The final cyclization step was achieved via an  intramolecular 
nitrene  insertion  reaction  by  the  heating  of  170 with  triethyl  phosphite,  yielding  the  tetracyclic 
compound 171 in 65% yield. Styelsamine C (128) was finally prepared by O‐demethylation of 171 
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Scheme 23. Synthesis of styelsamine (127, 148–152) and cystodytine analogues (139, 153–157):
(a) CeCl3¨ 7H2O, Ag2O, MeOH/AcOH (2:1), then 6 M HCl (6%–20%); (b) Ag2O (one equiv.), MeOH
(13%–79%).
In 2002, Skyler and Heathcock [3] reported that treatment of stylesamine B (127) with hydrochloric
acid (4 M) in methanol afforded the alkylamino analogue of stylesamine D 158 in quantitative yield.
Repeating this experiment, Copp isolated, besides the desired product 158, the unexpected O-methyl
analogue 159. With this O-methyl analogue 159 in hand, the authors were able to prepare the N-acyl
analogues 160–162. While acrylamide 160 and 2-phenylacetamide 161 were synthesized by treatment
of 159 with appropriate carboxylic acids in DMF and PyBOP, 3-phenylpropanamide 162 was prepared
from 159 by reaction with dihydrocinnamoyl chloride in THF (Scheme 24) [45].
In 2003, Nakahara and Kubo reported the first total synthesis of styelsamine C (128) [46,47].
This nine-step approach with an overall yield of 16% started with selective transfer hydrogenation
of 5-methoxy-2,4-dinitrotoluene (163) using cyclohexene and 10% palladium on carbon catalyst to
give 2-methoxy-4-methyl-5-nitroaniline (164). The following treatment with Meldrum’s acid furnished
enaminone 165, which was cyclized in refluxing diphenyl ether to afford 4-quinolone 166 (47% yield
over three steps). Reaction of 166 with phosphoryl bromide gave 4-bromoquinoline 167 in 78% yield.
The 4-phenylquinoline 168 was obtained in almost quantitative yield by the Suzuki cross-coupling
reaction of 167 with phenylboronic acid under standard conditions. The acidic methyl group at
C-6 of the nitroquinoline 168 was converted to an aldehyde in two steps. Treatment of 168 with
N,N-dimethylformamide dimethyl acetal at 170 ˝C (in the full paper [47] the authors present different
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conditions, N,N-dimethylformamide dimethyl acetal at 145 ˝C, but the same yield) furnished enamine
169 in 91% yield. Subsequent oxidative cleavage with NaIO4 in THF/water afforded aldehyde 170
in 90% yield. The final cyclization step was achieved via an intramolecular nitrene insertion reaction
by the heating of 170 with triethyl phosphite, yielding the tetracyclic compound 171 in 65% yield.
Styelsamine C (128) was finally prepared by O-demethylation of 171 with boron tribromide in 86%









acid, EtOH/toluene, K2CO3, Pd(PPh3)4  (94%);  (f) N,N‐dimethylformamide dimethyl  acetal,  170  °C 
(91%); (g) NaIO4, THF/H2O (90%); (h) P(OEt)3 (65%); (i) BBr3 in CH2Cl2 (86% over two steps). 
6. Sebastianine A 
Sebastianines A  (172) and B  (173) are members of a pyridoacridine subclass  that possesses a 
pyrrole  ring  fused  to  ring A  of  the  pyridoacridine  ring  system  (Figure  6).  In  2002,  Torres  et  al. 
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Sche e 25. Synthesis of styelsamine C (128): (a) 10% Pd/C, cyclohexene/EtOH (60%); (b) eldrum’s
acid, tri ethyl orthofor ate (94%); (c) diphenyl ether, reflux (83%); (d) POBr3 (78%); (e) phenylboronic
acid, Et /toluene, K2CO3, Pd(PPh3)4 (94%); (f) , -dimethylformamide di ethyl acetal, 170 ˝C
(91 ); (g) aI 4, T F/H2O (90%); (h) P(OEt)3 (65%); (i) BBr3 in CH2Cl2 (86% over two steps).
6. Sebastianine A
Sebastianines A (172) and B (173) are members of a pyridoacridine subclass that possesses a
pyrrole ring fused to ring A of the pyridoacridine ring system (Figure 6). In 2002, Torres et al. reported
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Figure 6. Structures of sebastianines A (172) and B (173). Figure 6. Structures of sebastianines A (172) and B (173).
One year later, Delfourne published the first total synthesis of sebastianine A (172) [49].
This approach, which stands in close relationship to the above-mentioned synthesis of
demethyldeoxyamphimedine (56) [12], again comprises a hetero-Diels-Alder cycloaddition as the key
step. The required dienophiles, N-tosylindole-4,7-dione 175 as well as the corresponding unprotected
indole-4,7-dione 176, were obtained via 4,7-dimethoxyindole in multistep procedures (five and six
steps). Cycloadditions with cinnanaldehyde-derived 1-azadieene 174 and subsequent re-aromatization
with MnO2 gave mixtures of regioisomers 177/179 (5:95) or 178/180 (60:40) in very poor yields
(6%–8%). Structures of the isomers were assigned only by analogy to the outcome of related
cycloadditions performed by another group. Subsequent cyclization of 178 under alkaline conditions
afforded sebastianine A (172) in 85% yield, and its regioisomer 183 was obtained in high yield by
prolonged treatment of N-tosyl intermediate 179 with NaOH under cyclization and subsequent




One  year  later,  Delfourne  published  the  first  total  synthesis  of  sebastianine  A  (172)  [49].   
This  approach,  which  stands  in  close  relationship  to  the  above‐mentioned  synthesis  of 
demethyldeoxyamphimedine  (56)  [12], again  comprises a hetero‐Diels‐Alder  cycloaddition as  the 




poor yields  (6%–8%). Structures of  the  isomers were assigned only by analogy  to  the outcome of 
related cycloadditions performed by another group. Subsequent cyclization of 178 under alkaline 
conditions afforded sebastianine A (172) in 85% yield, and its regioisomer 183 was obtained in high 
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7. Arnoamine-Type Pyridoacridines
Arnoamines A–D (184–187) are a unique type of pyridoacridine alkaloids, since they bear a pyrrole
ring fused to rings A and B of the pyrido[4,3,2-mn]acridine skeleton. Isolated in 1998 (arnoamines A and
B) and 2013 (arnoamines C and D) from two different ascidians (Cystodytes species), these pentacycles
are up to today the only known representatives of this pyridoacridine subclass (Figure 7) [50,51].
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Figure 7. Structures of arnoamines A (184), B (185), C (186), and D (187).
Th first total syntheses of arn amines A (184) and B (185) were reported in 2000 [52] and have
already been described in Delfourne’s review [6]. The key steps of this approach were the thermolysis
of an arylaminomethylene in Meldrum’s acid derivative for construction of the quinoline scaffold
(rings A and D), a Suzuki cross-coupling reaction of a functionalized 4-bromoquinoline (188) for the
introduction of the phenyl ring (C), annulation of the pyrrole ring via Fischer indole synthesis, followed
by cyclization under intramolecular N-arylation of the pyrrole ring (E) [52].
A related approach to arnoamine B (185) was reported by Nakahara et al. in 2007 [53]. Starting from
readily available 5-nitroquinoline 167 (see Scheme 25), alkaloid 185 was prepared in four steps with
an overall yield of 12%. In the first step, 167 was subjected to a palladium(0)-catalyzed Suzuki
cross-coupling reaction to give 4-(2-bromophenyl)quinoline 189 in 85% yield. Annulation of the pyrrole
ring was accomplished in low yield (17% over two steps) utilizing the Leimgruber-Batcho protocol
by condensation of the CH-acidic 6-methyl group of 189 with N,N-dimethylformamide dimethyl
acetal to give enamine 190 and subsequent reductive cyclization with zinc powder in 80% aqueous
acetic acid. Despite the low yield, this protocol is more convenient than Delfourne’s protocol starting
from the des-methyl compound 188 and utilizing a Fischer synthesis for construction of the pyrrole
ring. Finally, cyclization to arnoamine B (185) was accomplished in 81% yield under intramolecular
N-arylation of the pyrrole moiety of 191 under palladium(II) acetate catalysis (Scheme 27) [53].
Mar. Drugs 2016, 14, x  19 of 24 
 
quinoline  scaffold  (rings  A  and  D),  a  Suzuki  cross‐coupling  reaction  f  a  functionalized 
4‐bromoquinoline (188) for the introduction of the phenyl ring (C), annulation of the pyrrole ring via 





cross‐coupling  reaction  to  give  4‐(2‐bromophenyl)quinoline  189  in  85%  yield. Annulation  of  the 
pyrrole ring was accomplished in low yield (17% ov r two steps) utilizing the Leimgruber‐Batch  
protocol  by  c ndensation  of  the CH‐acidic  6‐methyl  group  of  189 with N,N‐dimethylformamide 
dimethyl acetal to give enamine 190 and subsequent reductive cyclization with zinc powder in 80% 
aqueous  acetic  acid.  Despite  the  low  yield,  this  protocol  is more  convenient  than  Delfourne’s 
protocol  starting  from  the  des‐methyl  compound  188  and  utilizing  a  Fischer  synthesis  for 
construction of the pyrrole ring. Finally, cyclization to arnoamine B (185) was accomplished in 81% 












196,  which  was  converted  to  enamine  197  by  treatment  with  Meldrum’s  acid  and  trimethyl 
orthoformate  in 95% yield. Subsequent  thermal  cyclization  in  refluxing diphenyl  ether  furnished 
pyrroloquinolone 198 in 80% yield. Arnoamine B analogue 200 was finally obtained by treating 198 
with  phosphoryl  chloride  (giving  199)  and  subsequent  radical  intramolecular  cyclization  using 
tributyltin hydride and azobis(isobutyronitrile) in 93% yield over two steps (Scheme 28) [54]. 
Scheme 27. Synthesis of arnoamine B (185): (a) from 167: 2-bromophenylboronic acid, H2O/toluene,
K2CO3, Pd(PPh3)4 (85%); (b) N,N-dimethylformamide dimethyl acetal, DMF (83%); (c) Zn, AcOH/H2O
(21%); (d) Pd(OAc)2, P(CMe3)3, K2CO3, xylene (81%).
Using a different approach, starting from a N-phenylindole 192, Radchenko et al. worked out
a simple and effective route to the pyrido[4,3,2-mn]pyrrolo[3,2,1-de]acridine core of arnoamine-type
pyridoacridines [54]. Synthesis of the arnoamine B analogue 200 started with O-methylation of 192
with dimethyl sulfate and sodium hydroxide to afford methyl ether 193 in almost quantitative yield.
The following nitration with nitric acid (75%) in acetic anhydride furnished a mixture of nitroindoles
194 and 195 in 63% and 30% yield. Raney nickel-catalyzed hydrogenation of 194 gave primary
amine 196, which was converted to enamine 197 by treatment with Meldrum’s acid and trimethyl
orthoformate in 95% yield. Subsequent thermal cyclization in refluxing diphenyl ether fur ished
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pyrroloquinolone 198 in 80% yield. Arnoamine B analogue 200 was finally obtained by treating
198 with phosphoryl chloride (giving 199) and subsequent radical intramolecular cyclization using
























Subarine  (212), a marine pyridyl benzo[c][2,7]naphthyridine alkaloid,  is closely related  to  the 
pyridoacridine family, as it is formally a seco analogue of ascididemin‐type alkaloids. This alkaloid 
was prepared following two different approaches by the Delfourne [56] and Bracher [57] groups. 
Scheme 28. Synthesis of arnoamine B analogue 200: (a) Me2SO4, 2 M NaOH, H2O, dioxane (95%);
(b) HNO3, Ac2O (194, 63% and 195, 30%); (c) from 194: H2, Raney nickel, isopropanol (no yield given);
(d) Meldrum’s acid, trimethyl orthoformate (95%); (e) diphenyl ether, reflux (80%); (f) POCl3 (96%);
(g) Bu3SnH, AIBN, benzene (97%).
In close relationship to this approach, Nakahara et al. achieved the synthesis of arnoamine B
(185) in five steps with an overall yield of 33% [55]. This total synthesis starts with a CuI-catalyzed
N-arylation reaction of 5-methoxy-6-nitroindole (201) with iodobenzene in toluene to give indole
202 in 80% yield. Following catalytic hydrogenation over 10% palladium on carbon in methanol
yielded 6-aminoindole 203. Annulation of the 4-pyridone ring was accomplished following the
methods described above by treating 203 with Meldru ’s acid in trimethyl orthoformate (66% yield
over two steps), followed by thermal cyclization of 204 upon h ating in efluxing diphenyl ether.
Subsequent trea me t with phosphoryl chloride affor ed chloro compound 205 in 70% yield over
two steps. The final intramolecular cyclization st p was p rformed using a large excess of tributyltin
hydride and azobis(isobutyronitrile) in toluene to furnish the desired alkaloid 185 in 90% yield
(Scheme 29) [55].
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Subarine  (212), a marine pyridyl benzo[c][2,7]naphthyridine alkaloid,  is closely related  to  the 
pyridoacridine family, as it is formally a seco analogue of ascididemin‐type alkaloids. This alkaloid 
was prepared following two different approaches by the Delfourne [56] and Bracher [57] groups. 
Scheme 29. Synthesis of arnoamine B (185) by Kubo: (a) iodobenzene, CuI, (CH2NHMe)2, K3PO4,
toluene (80%); (b) 10% Pd-C, methanol; (c) Meldrum’s acid, trimethyl orthoformate (66% over two
steps); (d) Ph2O, reflux; the POCl3 (70% over two steps); (e) Bu3SnH (30 equiv.), AIBN (15 equiv.),
toluene (90%).
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8. Subarine—A Formal Seco Analogue of Pyridoacridines
Subarine (212), a marine pyridyl benzo[c][2,7]naphthyridine alkaloid, is closely related to the
pyridoacridine family, as it is formally a seco analogue of ascididemin-type alkaloids. This alkaloid
was prepared following two different approaches by the Delfourne [56] and Bracher [57] groups.
Delfourne’s total synthesis of subarine (212) was accomplished in four steps with an
overall yield of 70% starting from intermediate 1,10-phenanthrolin-4-ol (206), itself obtained
in four steps from commercially available 8-aminoquinoline. Reaction of 206 with phosphoryl
bromide and phosphorus tribromide gave the corresponding bromo derivative 207. Subsequent
oxidative cleavage of 207 with potassium permanganate under alkaline conditions afforded the
binicotinic-type dicarboxylic acid 208. The following conversion to diester 209 was accomplished by
treatment of 208 with DCC and methanol. Palladium-catalyzed Stille cross-coupling reaction with
N-(tert-butoxycarbonyl)-2-(trimethylstannyl)aniline afforded the expected phenyl-binicotinate 210,
together with the already cyclized lactam 211. Subarine (212) was finally obtained by treating 211
with trifluoroacetic acid. In the case of 210, synthesis was accomplished through cleavage of the Boc
protecting group and a subsequent intramolecular cyclization reaction (Scheme 30) [56].
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furnished  the  mono‐2‐haloanilides  216  and  217  in  moderate  yields,  accompanied  by  the 
corresponding dianilides. The final cyclization step was accomplished by treating 2‐iodoanilide 216 
with  tributyltin  hydride  and  a  catalytic  amount  of  azobis(isobutyronitrile)  in  benzene  to  afford 
subarine  (212)  in  very  poor  yield  [57].  Significant  amounts  of  deiodination  product  218  were 
obtained in this reaction. Unfortunately, this approach gives only a very poor overall yield (Scheme 
31). 
Scheme 30. Synthesis of subarine (212) by Delfourne: (a) POBr3, PBr3 (79%); (b) KMnO4, KOH, H2O;
(c) DCC, MeOH (88% over two steps); (d) 2-(NHBoc)C6H4SnMe3, Pd(PPh3)4, 1,4-dioxane (210, 63% ;
211, 18%); (e) Et3N, CH2Cl2 (98% for both reactions).
A significantly shorter synthetic route towards the alkaloid subarine (212) was reported by Lotter
and Bracher in 2009 [57]. This four-step approach starts with the oxidation of 1,10-phenanthroline (213)
using potassium permanganate. The so-obtained dicarboxylate 214 was esterificated by treatment
with sulfuric acid in methanol to give the symmetric diester 215 in high yield. Amidation of
215 with 2-haloanilines under Weinreb conditions (trimethylaluminum, heptane) furnished the
mono-2-haloanilides 216 and 217 in moderate yields, accompanied by the corresponding dianilides.
The final cyclization step was accomplished by treating 2-iodoanilide 216 with tributyltin hydride and
a catalytic amount of azobis(isobutyronitrile) in benzene to afford subarine (212) in very poor yield [57].
Significant amounts of deiodination product 218 were obtained in this reaction. Unfortunately, this
approach gives only a very poor overall yield (Scheme 31).
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Sche e 31. Synthesis of subarine (212) by Lotter and Bracher: (a) KMnO4, KOH, H2O (b) H2S 4,
e (73 over t o steps); (c) 2-iodoaniline/2-bromoaniline, CH2Cl2, Me3Al, heptane (216, 40%;
217, 35%); (d) Bu3SnH, AIBN, benzene (7% from 216).
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